[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″]
Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation Summit. Detailing how this technology benefits a variety of conditions, Guillaume explains how the NPP can be leveraged to treat, post cataract surgery inflammation, dry eye, plethoritis and a demonstration to back of the eye.
Dr. Guillaume Pfefer joined Kala in July 2012 as the company’s President, CEO and Member of the Board of Directors. Dr. Pfefer brings to Kala more than 15 years of experience in the pharmaceutical industry leading commercial, strategic, R&D, and industrial operations.